Share this article

According to GlobalData, COBRA is one of 45 product lines sold in the US coronary stents market; these product lines are sold by 8 different manufacturers. The price of the COBRA device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Coronary Stents - CeloNova BioSciences Inc - COBRA

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.

In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as CeloNova BioSciences apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.

CeloNova BioSciences overview

CeloNova BioSciences Inc (CeloNova BioSciences) is a medical device company that develops, manufactures and markets products for the treatment of cardiovascular disease. The company offers coronary stent systems based on its technology platform Polyzene-F core a chemical compound with an array of bioscience and industrial applications. Its proprietary investigational device COBRA PzF stent, with its Polyzene-F nanocoating help reduce bleeding after percutaneous coronary intervention (PCI). CeloNova BioSciences conducted clinical trials such as PzF shield trial and COBRA reduce trial. It has operations in Germany, France, and the Netherlands. CeloNova BioSciences is headquartered in Carlsbad, California, the US.

For a complete picture of COBRA, Coronary Stents pricing in the US, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.